This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Pocock, S. J Search for Related Content PubMed PubMed Citation Articles by Pocock, S. J Social Bookmarking                         What's this?

Current controversies in data monitoring for clinical trials

Medical Statistics Unit, London School of Hygiene and Tropical Medicine, London, UK, stuart.pocock{at}lshtm.ac.uk

This article presents some real-life challenges faced by clinical trial Data Monitoring Committees (DMCs), with the aim of clarifying some of the controversial issues that relate to both statistical stopping boundaries and DMC decision-making. Specific attention is given to what constitutes a sensible statistical boundary for stopping a trial early for benefit, bearing in mind that one usually needs proof beyond reasonable doubt of a treatment benefit sufficient to alter future clinical practice. Appropriate choices of stopping boundary for harm and futility are also discussed. The examples serve to illustrate that the practicalities of DMC decision-making require wise judgements based on a totality of evidence, making any statistical boundary just an objective guideline rather than a definitive stopping rule.

Clinical Trials, Vol. 3, No. 6, 513-521 (2006)
DOI: 10.1177/1740774506073467


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. J. Gibbons, A. Fugh-Berman, P. S. Chan, B. K. Nallamothu, R. A. Hayward, E. R. Jenny-Avital, K.-H. Mak, E. S.-Y. Chan, L. A. Pierard, C. E. Davis, et al. Rosuvastatin in Patients with Elevated C-Reactive Protein N. Engl. J. Med., March 5, 2009; 360(10): 1038 - 1042. [Full Text] [PDF]

				B. Freidlin and E. L. Korn Monitoring for Lack of Benefit: A Critical Component of a Randomized Clinical Trial J. Clin. Oncol., February 1, 2009; 27(4): 629 - 633. [Abstract] [Full Text] [PDF]

				K. Thorlund, P J Devereaux, J. Wetterslev, G. Guyatt, J. P A Ioannidis, L. Thabane, L.-L. Gluud, B. Als-Nielsen, and C. Gluud Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int. J. Epidemiol., February 1, 2009; 38(1): 276 - 286. [Abstract] [Full Text] [PDF]

				W. M. Ankum, J. B. Reitsma, and M. Offringa IVF with preimplantation genetic screening, a promising new treatment with unexpectedly negative health outcomes: the Hippocratic role of Data Monitoring Committees Hum. Reprod., January 1, 2008; 23(1): 1 - 3. [Abstract] [Full Text] [PDF]

				S. N. Goodman Stopping at Nothing? Some Dilemmas of Data Monitoring in Clinical Trials Ann Intern Med, June 19, 2007; 146(12): 882 - 887. [Abstract] [Full Text] [PDF]